These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 4070930)

  • 1. Carcinogenicity testing of antitumor agents.
    Hottendorf GH
    Toxicol Pathol; 1985; 13(3):192-9. PubMed ID: 4070930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
    Battershill JM; Fielder RJ
    Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies.
    Mitsumori K; Koizumi H; Nomura T; Yamamoto S
    Toxicol Pathol; 1998; 26(4):520-31. PubMed ID: 9715511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The mutagenic and carcinogenic activity of chemical compounds].
    Rakitskiĭ VN; Turusov VS
    Vestn Ross Akad Med Nauk; 2005; (3):7-9. PubMed ID: 15852703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinogenicity of mutagens: predictive capability of the Salmonella mutagenesis assay for rodent carcinogenicity.
    Zeiger E
    Cancer Res; 1987 Mar; 47(5):1287-96. PubMed ID: 3815340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutagenicity, carcinogenicity, and teratogenicity of acrylonitrile.
    Léonard A; Gerber GB; Stecca C; Rueff J; Borba H; Farmer PB; Sram RJ; Czeizel AE; Kalina I
    Mutat Res; 1999 May; 436(3):263-83. PubMed ID: 10354525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiological and experimental applications to occupational cancer prevention.
    Vainio H; Hemminki K
    J UOEH; 1989 Mar; 11 Suppl():323-45. PubMed ID: 2664947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing of chemicals for carcinogenic activities and some problems related to the assessment of carcinogenic risks to men.
    Schramm T; Teichmann B
    Pol J Pharmacol Pharm; 1979; 31(6):639-45. PubMed ID: 550120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental investigations into the carcinogenic effect of antitumor and immunosuppressive agents.
    Brock N; Schneider B; Stekar J; Pohl J
    J Cancer Res Clin Oncol; 1989; 115(4):309-28. PubMed ID: 2760096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of transplacental exposure into routine carcinogenicity bioassays.
    Swenberg JA
    Natl Cancer Inst Monogr; 1979 May; (51):265-8. PubMed ID: 481580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medium-term bioassays in rats for rapid detection of the carcinogenic potential of chemicals.
    Shirai T; Hirose M; Ito N
    IARC Sci Publ; 1999; (146):251-72. PubMed ID: 10353390
    [No Abstract]   [Full Text] [Related]  

  • 13. Carcinogenicity, mutagenicity and teratogenicity of nickel.
    Léonard A; Gerber GB; Jacquet P
    Mutat Res; 1981 Jul; 87(1):1-15. PubMed ID: 7035928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1,3-butadiene: cancer, mutations, and adducts. Part III: In vivo mutation of the endogenous hprt genes of mice and rats by 1,3-butadiene and its metabolites.
    Walker VE; Meng Q
    Res Rep Health Eff Inst; 2000 Mar; (92):89-139; discussion 141-9. PubMed ID: 10925840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative comparison between in vivo DNA adduct formation from exposure to selected DNA-reactive carcinogens, natural background levels of DNA adduct formation and tumour incidence in rodent bioassays.
    Paini A; Scholz G; Marin-Kuan M; Schilter B; O'Brien J; van Bladeren PJ; Rietjens IM
    Mutagenesis; 2011 Sep; 26(5):605-18. PubMed ID: 21642616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of short-term in vitro mutagenicity tests to predict the animal carcinogenicity of hair dyes.
    Burnett CM; Corbett JF
    Food Chem Toxicol; 1987 Sep; 25(9):703-7. PubMed ID: 3653824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compendium of chemical carcinogens by target organ: results of chronic bioassays in rats, mice, hamsters, dogs, and monkeys.
    Gold LS; Manley NB; Slone TH; Ward JM
    Toxicol Pathol; 2001; 29(6):639-52. PubMed ID: 11794380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinogenic, mutagenic, teratogenic workshop.
    Suit H; Hall E; Frei E
    Cancer Clin Trials; 1981; 4 Suppl():37-41. PubMed ID: 7307224
    [No Abstract]   [Full Text] [Related]  

  • 19. An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide.
    McCarroll N; Keshava N; Cimino M; Chu M; Dearfield K; Keshava C; Kligerman A; Owen R; Protzel A; Putzrath R; Schoeny R
    Environ Mol Mutagen; 2008 Mar; 49(2):117-31. PubMed ID: 18240158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What do animal cancer tests tell us about human cancer risk?: Overview of analyses of the carcinogenic potency database.
    Gold LS; Slone TH; Ames BN
    Drug Metab Rev; 1998 May; 30(2):359-404. PubMed ID: 9606609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.